Navigation Links
Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
Date:3/31/2008

veloping new diagnostic tests or novel markers, the Company's ability to fund development of new diagnostic tests and novel markers and the amount of resources the Company determines to apply to novel marker development and commercialization, the Company's ability to obtain additional financing if required on favorable terms or at all, failure to obtain FDA clearance or approval for particular applications, the Company's ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in the Company's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations may not be indicative of future results for the reasons set forth above.

The company does not assume any obligation to update any forward-looking statements or other information contained in this document.

Contact:

Matt Clawson

Allen & Caron, Inc.

(949) 474-4300

matt@allencaron.com

TABLES FOLLOW

Clarient , Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

Revenue $12,357 $8,055 $42,995 $27,723

Cost of revenue 5,993 4,469 22,304 15,566

Gross profit 6,364 3,586 20,691 12,157

Selling, general and

admi
'/>"/>

SOURCE Clarient, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
2. Clarient to Commercialize Novel Breast Cancer Profile
3. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014 Tigercat ... Phase 2 study evaluating the investigational oral NK-1 ... patients with severe, chronic itch who are unresponsive ... care, including topical steroids and antihistamines. ... in Visual Analog Scale (VAS) itch score from ...
(Date:12/15/2014)... 2014  GlassesOff Inc. (OTCBB: GLSO) announced today the ... independent director of the Company,s Board of Directors. ... as its CEO until its acquisition by Stanley ... transaction. Recognized as the inventor of the first Wi-Fi-based ... Wi-Fi -based RFID solutions focused on improving operational efficiency, ...
(Date:12/13/2014)... Maryland (PRWEB) December 12, 2014 Clarassance, ... today announced its new name: Therabron Therapeutics , ... therapy and bronchioles (a type of structure in the ... the company’s mission to develop novel protein therapeutics for ... of directors decided to change the name to mark ...
(Date:12/13/2014)... 2014 QuickSTAT is making significant investments ... Chain capabilities, and is delighted to announce the opening ... serve Life Science clients in the region. , QuickSTAT ... warehouse, will provide 24/7 transportation and logistics services, as ... patient-clinical specimens, API, following IATA rules and EU GDP ...
Breaking Biology Technology:Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2
... -- JERUSALEM and NEEDHAM, Massachusetts, August 18, 2010, ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in ...
... Fuels, Inc., a company focused on commercially producing low-carbon ... has produced cellulosic methanol from the initial phase of ... using non-food biomass. The first phase of ... thermo-chemical process, which uses heat, pressure, and steam to ...
... VANCOUVER, Canada, Aug. 17 Xenon Pharmaceuticals Inc. announced ... trial evaluating its novel topical XEN402 therapy for the ... developed by Xenon as a topical ointment formulation and ... 1 study in normal human volunteers.  The product was ...
Cached Biology Technology:Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 2Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 3Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 4Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 5Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 6Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 7Range Fuels Produces Cellulosic Methanol From First Commercial Cellulosic Biofuels Plant 2Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402. 2
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... foot ulcers are a common problem for diabetics and are ... leg amputations in these patients. There is currently no effective ... new research offers hope. French researchers found that diabetic ... prolinespecific molecules found in proteinshowed better wound healing over rats ...
... of the species that inhabit the world,s oceans may remain ... species have been described in the last decade than in ... November 15 in the Cell Press publication Current Biology ... of the worlda massive collaborative undertaking by hundreds of experts ...
... college-age video game enthusiasts teach young surgeons-in-training? ... University of Texas Medical Branch at Galveston (UTMB) ... the superior hand-eye coordination and hand skills gained ... needed to perform today,s most technologically-advanced robotic surgeries. ...
Cached Biology News:Arginine and proline enriched diet may speed wound healing in diabetes 2At least one-third of marine species remain undescribed 2Young gamers offer insight to teaching new physicians robotic surgery 2Young gamers offer insight to teaching new physicians robotic surgery 3
... The Rotofor purification system, 100-120 V, is ... liquid-phase isoelectric focusing (IEF). The system includes ... (60 ml) focusing chambers, chassis, harvesting apparatus, ... ampholytes (pH 3-10), 60 ml syringe, colored ...
... BCIP/NBT Chromogen system consists of ... in a single component,solution. The ... the presence of alkaline phosphatase ... minimal background noise. ,The System ...
Mouse monoclonal antibody raised against a partial recombinant VEGFB. NCBI Entrez Gene ID = VEGFB...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
Biology Products: